Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 0.00% is 100% above its 5-year average of -97.01%, near the high end of its 5-year range (-548.90%–40.32%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
-44.33%
GROSS MARGIN AVG 5Y
-97.01%
GROSS MARGIN AVG 10Y
-71.72%
GROSS MARGIN AVG 15Y
-99.91%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+100.00%
CURRENT VS 5Y AVG
+100.00%
CURRENT VS 10Y AVG
+100.00%
CURRENT VS 15Y AVG
+100.00%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.44%
median of 787 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Market Cap
$5.37M
Gross Margin
48.63%
TTM Avg
44.74%
3Y Avg
40.32%
5Y Avg
43.55%
Market Cap
$5.20M
Gross Margin
100.00%
TTM Avg
50.00%
3Y Avg
43.60%
5Y Avg
29.07%
Market Cap
$5.18M
Gross Margin
77.68%
TTM Avg
77.66%
3Y Avg
77.69%
5Y Avg
77.69%
Market Cap
$5.16M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.61M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pulmatrix, Inc. (PULM) | $5.41M | 0.00% | 0.00% | -44.33% | -97.01% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.37M | 48.63% | 44.74% | 40.32% | 43.55% |
| Soligenix, Inc. (SNGX)vs › | $5.37M | 0.00% | 0.00% | -30.08% | -366.57% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.30M | 0.00% | 0.00% | 0.00% | 0.00% |
| Alzamend Neuro Inc (ALZN)vs › | $5.25M | 0.00% | 0.00% | 0.00% | 0.00% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.20M | 100.00% | 50.00% | 43.60% | 29.07% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.18M | 77.68% | 77.66% | 77.69% | 77.69% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.16M | 0.00% | 0.00% | 0.00% | 0.00% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.61M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.70M | -1.29% | -3.77% | 16.02% | 20.70% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | -100.00% |
| 2024-09-30 | -122.40% |
| 2024-06-30 | -82.60% |
| 2024-03-31 | 40.32% |
| 2023-12-31 | -59.67% |
| 2023-09-30 | -126.07% |
| 2023-06-30 | -125.87% |
| 2023-03-31 | -158.44% |
| 2022-12-31 | -161.53% |
| 2022-09-30 | -182.43% |
| 2022-06-30 | -225.85% |
| 2022-03-31 | -257.67% |
| 2021-12-31 | -548.90% |
| 2021-09-30 | -276.61% |
| 2021-06-30 | -101.46% |
| 2021-03-31 | -177.41% |
| 2020-12-31 | -517.20% |
| 2020-09-30 | 11.41% |
| 2020-06-30 | 9.03% |
| 2020-03-31 | -91.42% |
| 2019-12-31 | -149.73% |
| 2019-09-30 | -134.50% |
| 2019-06-30 | 34.34% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | -2005.23% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | -681.49% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | -2270.94% |
| 2016-09-30 | -2370.49% |
| 2016-06-30 | -838.85% |
| 2016-03-31 | -766.16% |
| 2015-12-31 | -796.73% |
| 2015-09-30 | -236.87% |
| 2015-06-30 | -847.06% |
| 2015-03-31 | -774.29% |
| 2014-12-31 | -272.61% |
| 2014-09-30 | -6330.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | -21925.00% |
| 2013-12-31 | 0.00% |
| 2013-09-30 | 0.00% |
| 2013-06-30 | 0.00% |
| 2013-03-31 | 0.00% |
| 2012-12-31 | 0.00% |
| 2012-09-30 | 0.00% |
| 2012-06-30 | 0.00% |
